Skip to content
Open access · CC-BY via OpenAlex

Mitochondrial DNA methylation and mitochondria-related epigenetics in neurodegeneration

Fabio Coppedè

Neural Regeneration Research · 2023 · ▲ 20 citations

Abstract

Mitochondria are cytoplasmic organelles referred to as the powerhouse of the cell because they are primarily involved in oxidative phosphorylation and energy production. They are particularly abundant in tissues with high energy demands, including muscle, liver, and brain, and mitochondrial dysfunction(definition), oxidative mitochondrial DNA (mtDNA) damage, and impaired mitochondrial dynamics have often been associated with neurodegeneration. The mtDNA is a circular, double-stranded molecule present in two to ten copies per mitochondrion and encodes 13 subunits of the mitochondrial respiratory chain as well as 22 transfer RNAs and two ribosomal RNAs. The existence of mitochondrial epigenetics, and in particular mtDNA methylation, has been largely debated, but a growing body of literature suggests that impaired mtDNA methylation may be involved in neurodegeneration (Coppedè and Stoccoro, 2019). Furthermore, there is increasing evidence for bidirectional crosstalk between the nuclear and mitochondrial genomes to allow coordinated gene expression in response to different cellular stressors. This crosstalk is mainly mediated by epigenetic mechanisms, but is unfortunately still poorly understood in neurodegenerative diseases (Coppedè, 2021). In this perspective, after a brief description of the available literature on impaired mtDNA methylation in neurodegenerative diseases, the author discusses the potential factors contributing to these alterations and their crosstalk with nuclear epigenetics. Mitochondrial epigenetics in neurodegeneration: The mtDNA lacks histones, so mtDNA methylation and hydroxymethylation are the most studied mitochondrial epigenetic modifications in patients with neurodegenerative diseases. The existence of mtDNA methylation has long been questioned, but is largely supported by recent studies. For example, a recent epigenome-wide study of human brain samples revealed that mtDNA methylation patterns are relatively low but conserved. Indeed, mtDNA methylation averages about 2%, occurs mainly at non-CpG sites, and is likely to be non-biologically relevant at several loci. However, peaks of mtDNA methylation have been observed at several sites, including sites within the regulatory D-loop region, which regulates mtDNA transcription and replication, and within the MT-ND2, MT-ND4, MT-ND5, and MT-ATP6 genes, which encode subunits of complex I (nicotinamide adenine dinucleotide dehydrogenase) or complex V (adenosine triphosphate synthase), respectively (Devall et al., 2022). This genome-wide study corroborates the results of several previous studies in patients with neurodegenerative diseases that we recently reviewed, which collectively reported very low levels of mtDNA methylation in both blood and postmortem brain regions of patients, but with some peaks at specific loci, including the regulatory D-loop region, that may be biologically relevant and warrant further investigation. For example, an inverse correlation between methylation levels of the D-loop region and mtDNA copy number has often been observed, and given the regulatory function of the D-loop, it has been suggested that DNA methylation levels of this region could regulate both transcription and replication of mtDNA (Coppedè and Stoccoro, 2019). Further support for the existence and biological function of mtDNA methylation comes from a recent study showing that the mtDNA is extensively methylated during the transition from blastocysts to post-implantation embryos, and that the primary function of this wave of de novo mtDNA methylation is to protect the mitochondrial genome from oxidative damage (Yue et al., 2022). Methylation levels of the D-loop regulatory region have been extensively studied in biological samples from humans with neurodegenerative diseases and in animal models of these disorders (Figure 1). Blanch et al. (2016) analyzed the entorhinal cortex of human postmortem brains in the early stages of Alzheimer’s disease (AD) and observed higher levels of D-loop methylation than in the entorhinal cortex of matched control brains. Furthermore, they observed a dynamic pattern of D-loop methylation levels with disease progression in cortical regions of animal models of AD, namely transgenic amyloid precursor protein/presenilin 1 (APP/PS1) mice. A similar dynamic D-loop methylation pattern was observed by us in blood DNA samples from AD patients. Indeed, D-loop methylation levels were higher than those observed in control blood samples in the prodromal stages of AD, but decreased in advanced stages of AD (Stoccoro et al., 2022). Decreased D-loop methylation levels have been described postmortem in the substantia nigra of PD patients compared to controls, but no differences in methylation levels of this region were observed when comparing PD and control blood samples (Blanch et al., 2016; Stoccoro et al., 2021). In patients with amyotrophic lateral sclerosis, a significant decrease in D-loop methylation, accompanied by an increase in mtDNA copy number, was observed in blood DNA samples, particularly in carriers of superoxide dismutase 1 (SOD1) gene mutations (Stoccoro et al., 2018). Regions of mtDNA other than the D-loop have been less frequently examined in human samples and, except for reduced MT-ND1 methylation levels observed in the entorhinal cortex of patients at early stages of AD-related pathology (Blanch et al., 2016), increases in 12S rRNA gene methylation and in the methylation levels of the mitochondrial cytochrome b (mt-Cytb) and cytochrome c oxidase II (mt-Co2) genes were observed in the hippocampi of APP/PS1 transgenic mice (Xu et al., 2021).Figure 1: Key mitochondrial epigenetic findings in neurodegenerative diseases.Studies investigating mtDNA methylation have mainly been performed in post-mortem tissues, blood samples, and in the brain of animal models of neurodegeneration. Studies in Alzheimer’s disease tissues and animal models are shown in red, those in Parkinson’s disease samples in blue, and those

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.4103/1673-5374.379045
Canonical
link ↗
Fetched
2026-10-04 MST

Cite this

APA
Coppedè, F. (2023). Mitochondrial DNA methylation and mitochondria-related epigenetics in neurodegeneration. <em>Neural Regeneration Research</em>. https://doi.org/10.4103/1673-5374.379045
Vancouver
Coppedè F. Mitochondrial DNA methylation and mitochondria-related epigenetics in neurodegeneration. Neural Regeneration Research. 2023. doi:10.4103/1673-5374.379045.
BibTeX
@article{fabio2023Mitoch, title = {Mitochondrial DNA methylation and mitochondria-related epigenetics in neurodegeneration}, author = {Fabio Coppedè}, journal = {Neural Regeneration Research}, year = {2023}, doi = {10.4103/1673-5374.379045}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings